The Motley Fool··Lee SamahaOvid Therapeutics Surges 18% on Positive Phase 1 Data for OV329 Epilepsy Drug
Ovid Therapeutics surges 18% after Phase 1 data shows OV329 epilepsy drug eliminated safety concerns. Company secures $60M to fund Phase 2 trials.
OVIDbiotechprivate placement